Novo Nordisk reported DKK138.54B in Equity Capital and Reserves for its fiscal quarter ending in March of 2025.


Equity Capital And Reserves Change Date
ANI Pharmaceuticals USD 436.76M 18.14M Jun/2025
Aurora Cannabis CAD 588.68M 15.76M Jun/2025
Bausch Health Companies USD 147M 1.33B Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Canopy Growth CAD 488.98M 102.49M Jun/2025
Corcept Therapeutics USD 635.79M 47.49M Jun/2025
Drreddys Laboratories INR 353.76B 36.03B Jun/2025
Eli Lilly USD 18.27B 2.43B Jun/2025
GlaxoSmithKline GBP 14.35B 197M Jun/2025
Merck USD 49.06B 725M Jun/2025
Novartis USD 42.05B 3.6B Jun/2025
Novo Nordisk 168.07B 29.53B Jun/2025
Novo Nordisk DKK 138.54B 18.02B Mar/2025
Pacira USD 757.77M 40.77M Jun/2025
Perrigo USD 4.47B 108.3M Jun/2025
Prestige Brands USD 1.86B 20.58M Jun/2025
Sanofi 70.28B 3.8B Jun/2025
Supernus Pharmaceuticals USD 1.06B 33.2M Jun/2025
Zoetis USD 4.98B 322M Jun/2025